Compliance and study completion
allergy, liver dysfunction, fatigue, allergies
ALLERGY, ALLERGIES
All patients who received at least one cycle of nab-PTX were included in the safety and response analyses. Thirty-eight (88.4%) patients completed all four cycles of nab-PTX with T-mab and P-mab. Four patients discontinued nab-PTX because of liver dysfunction, and one because of allergy. Dose reduction was required in seven (16.3%) patients, and dose delay was required in 12 patients (27.9%). Consequently, 38 patients received EC, 30 of whom completed the regimen (78.9%). Two patients discontinued EC owing to allergies and fatigue. For this, dose reduction was required in 12 patients (31.6%) and dose delay was required in 11 patients (28.9%). Finally, 33 of the 43 patients (76.7%) completed the entire regimen. All the patients underwent curative surgery after chemotherapy. None of the patients discontinued the protocol owing to protocol deviation.